Table 2.
Treatment-related adverse events
| Arm A: Daratumumab (n=15) | Arm B: Edicotinib (n=10) |
Total (n=25) | ||||
| All | Grade 3+ | All | Grade 3+ | All | Grade 3+ | |
| Adverse event | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Any event | 13 (87%) | 3 (20%) | 8 (80%) | 0 (0%) | 21 (80%) | 3 (12%) |
| Infusion reaction | 5 (33%) | 2 (13%) | 0 (0%) | 0 (0%) | 5 (20%) | 2 (8%) |
| Urticaria | 1 (7%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (4%) | 1 (4%) |
| AST increased | 0 (0%) | 0 (0%) | 4 (40%) | 0 (0%) | 4 (16%) | 0 (0%) |
| Fatigue/malaise | 3 (20%) | 0 (0%) | 1 (10%) | 0 (0%) | 4 (16%) | 0 (0%) |
| White blood cell decreased | 2 (13%) | 0 (0%) | 2 (20%) | 0 (0%) | 4 (16%) | 0 (0%) |
| Anemia | 1 (7%) | 0 (0%) | 2 (20%) | 0 (0%) | 3 (12%) | 0 (0%) |
| Constipation | 2 (13%) | 0 (0%) | 1 (10%) | 0 (0%) | 3 (12%) | 0 (0%) |
| Creatinine increased | 1 (7%) | 0 (0%) | 2 (20%) | 0 (0%) | 3 (12%) | 0 (0%) |
| Hyperglycemia | 1 (7%) | 0 (0%) | 2 (20%) | 0 (0%) | 3 (12%) | 0 (0%) |
| Paresthesia | 2 (13%) | 0 (0%) | 1 (10%) | 0 (0%) | 3 (12%) | 0 (0%) |
| ALT increased | 1 (7%) | 0 (0%) | 1 (10%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Chloride decreased | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Concentration impairment | 1 (7%) | 0 (0%) | 1 (10%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Dyspepsia/acid reflux | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Headache | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Myalgia | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Nausea | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Rash | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Rhinitis | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Sore throat | 2 (13%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Abdominal pain | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Alk phos increased | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Alopecia | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Bloating/abdominal distension | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Blurred vision | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| CO2 decreased | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Confusion | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Cough | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Diarrhea | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Dysphagia | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Dysuria | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Ear pain | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Influenza-like symptoms | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Hyperkalemia | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Hyponatremia | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Hypophosphatemia | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Lymphocyte count decreased | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Nocturia | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Pain | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Platelet count decreased | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Pruritus | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Shingles | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Sinus pain | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| T3 decreased | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Tremor | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Wheezing | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Yellow skin tone | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 0 (0%) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.